Treatment of extensive small cell lung cancer with carboplatin and teniposide.

The combination of carboplatin and teniposide has been evaluated in a phase II trial including 47 previously untreated patients with extensive small cell lung cancer. Treatment was given at monthly intervals at a dose of 200 mg/m2 of carboplatin intravenously on day 1 and teniposide at a daily dose of 60 mg/m2 intravenously on days 1-5. Treatment response was complete in 4 (8.

Bladder tumour treatment in the aarhus region. 25 years of experience.

We report on the clinical studies of bladder tumours carried out at the centre for oncology in the Aarhus area and describe the experience and results of the past three decades. The 1960's saw the replacement of intracavitary techniques with external megavoltage irradiation. In the 1970's a large-scale regional trial was conducted assessing irradiation, which was now the dominant treatment principle, at all stages of the disease.

Orgotein in radiation treatment of bladder cancer. A report on allergic reactions and lack of radioprotective effect.

The possible protective effect of orgotein (a superoxide dismutase) on radiation cystitis and proctitis was studied in patients with carcinoma of the urinary bladder. A double-blind study in 60 patients was planned but due to unacceptable side effects only 30 patients were included. Radiation treatment was given with curative intent at a dose of 63 Gy in 30 fractions.

Small cell anaplastic carcinoma of the lung. The Aarhus experience 1976-1981.

Over a 6-year period 179 patients with small cell carcinoma of the lung (SCLC), 152 with limited disease, 25 with extensive disease, and 2 who were not staged, were treated with chest irradiation and combination chemotherapy with CCNU, adriamycin and vinblastine. For all patients the 2-year survival was 19.9 +/- 3 per cent, and the 5-year survival 11.

Lack of radiation protective effect of orgotein in normal and malignant mammalian cells.

The potential radiation protective effect of orgotein, a metalloprotein with superoxide dismutase activity, was investigated in L1A2 tumour cells in vitro, jejunal crypt cells and C3H mouse mammary carcinoma in vivo. No effect of orgotein, given either 2 hours before irradiation or 30 min after, was observed compared to the effect of irradiation alone. Thus, it was concluded that orgotein did not influence the primary radiation response in air in mammalian cells.